DRIO vs. BDMD, VANI, APYX, NTRB, LUNG, ICCM, QTI, TELA, CTSO, and SURG
Should you be buying DarioHealth stock or one of its competitors? The main competitors of DarioHealth include Baird Medical Investment (BDMD), Vivani Medical (VANI), Apyx Medical (APYX), Nutriband (NTRB), Pulmonx (LUNG), IceCure Medical (ICCM), QT Imaging (QTI), TELA Bio (TELA), Cytosorbents (CTSO), and SurgePays (SURG). These companies are all part of the "medical equipment" industry.
DarioHealth vs. Its Competitors
Baird Medical Investment (NASDAQ:BDMD) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.
In the previous week, Baird Medical Investment and Baird Medical Investment both had 2 articles in the media. Baird Medical Investment's average media sentiment score of 1.33 beat DarioHealth's score of 0.95 indicating that Baird Medical Investment is being referred to more favorably in the media.
Baird Medical Investment has a net margin of 0.00% compared to DarioHealth's net margin of -162.73%. Baird Medical Investment's return on equity of 0.00% beat DarioHealth's return on equity.
Baird Medical Investment has a beta of -0.97, suggesting that its stock price is 197% less volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by company insiders. Comparatively, 11.2% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Baird Medical Investment has higher earnings, but lower revenue than DarioHealth.
DarioHealth has a consensus target price of $40.00, suggesting a potential upside of 462.59%. Given DarioHealth's stronger consensus rating and higher probable upside, analysts plainly believe DarioHealth is more favorable than Baird Medical Investment.
Summary
DarioHealth beats Baird Medical Investment on 6 of the 11 factors compared between the two stocks.
Get DarioHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DarioHealth Competitors List
Related Companies and Tools
This page (NASDAQ:DRIO) was last updated on 9/14/2025 by MarketBeat.com Staff
